As a proof-of-concept, we developed a new in vitro tumor cell-binding assay system, the 64Cu-TuBA system, using a panel containing nine candidate 64Cu-labeled antibodies: 64Cu-anti-EGFR antibodies (cetuximab and panitumumab), anti-HER2 antibodies (trastuzumab and pertuzumab), anti-HER3, anti-TfR, anti-EpCAM, anti-LAT1, and anti-CD98 antibodies (Table 1). The gene discussed is TFRC; the disease is neoplasm.